Safety study of Ingavirin Forte in healthy volunteers
Part of Infections, Lungs & breathing clinical trials.
This trial tests how safe and tolerable different doses of Ingavirin Forte are in healthy people. It helps find the right dose for future studies.
Summary written for real people, not researchers, by Clin2.
Who can take part
- Be between 18 and 45 years old and of Caucasian race
- Be in good health based on a medical check-up
- Have a body weight between 55 kg (men) or 45 kg (women) and a BMI between 18.5 and 30
- Have normal blood pressure (100-130/70-85), heart rate (60-89), and temperature (36.0-36.9°C)
- Agree to use birth control during the study and for 30 days after
- Not be pregnant, nursing, or planning to get pregnant
- Not smoke more than 10 cigarettes a day or drink too much alcohol
- Have no chronic diseases or allergies to the study drug or its ingredients
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study compares two versions of an antiviral medicine called Ingavirin to see how your body processes them and whether they are safe. Researchers will give you the medicine on an empty stomach and after eating to understand how food affects how your body absorbs it.
This trial tests different doses of Ingavirin Forte capsules for treating influenza and other respiratory viruses. It may help people with fever, cough, sore throat, and body aches who have been sick less than 48 hours.
This trial tests how the body reacts to a specific flu virus (pH1N1) in a controlled setting. Healthy volunteers are exposed to the virus to help researchers understand the infection and test treatments. You will be monitored closely and given antiviral medication if needed.
This trial studies whether Apomivir works and is safe for people who likely have the flu and test positive for influenza A or B. You may help researchers learn if treating early can reduce flu illness and side effects.
This first-in-human study tests the safety of a new medicine called VNT-101. Healthy adults aged 18 to 59 who do not smoke and have no major health problems may be able to join. The goal is to see how the body handles the drug and if it is safe.
This Phase 2 study compares antiviral medicines in adults who have early, flu-like symptoms and test positive for influenza. It aims to see which antiviral treatment works best and is safe for people treated soon after symptoms start.
Hear when a new Influenza trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.